Deep Brain Stimulation in the Bed Nucleus of Stria Terminalis in Obsessive-Compulsive Disorder?1-Year Follow-up

BACKGROUND: Deep brain stimulation (DBS) is under investigation as a treatment for therapy-refractory obsessive-compulsive disorder (OCD). As a crucial part of the anxiety circuit, the bed nucleus of stria terminalis (BNST) has been proposed as a target for DBS in OCD. Here, we investigate clinical outcomes and safety of DBS in the BNST in a series of 11 participants with severe therapy refractory OCD. METHODS: Eleven consecutive participants diagnosed with refractory OCD were treated with BNST DBS and completed follow-up. The primary outcome was a change in scores of the Yale Brown Obsessive Compulsive Scale (YBOCS) at 1 year after surgery. Secondary outcomes included changes in scores of the Montgomery-& Aring;sberg Depression Rating Scale (MADRS) and the Global Assessment of Functioning. RESULTS: At baseline, the mean +/- SD YBOCS score was 33 +/- 3.0, MADRS score was 29 +/- 4.5, and GAF score was 49 +/- 5.4. One year after DBS, mean +/- SD YBOCS score was 20 +/- 4.8 (38% improvement (range 10%-60%) P < 0.01), MADRS score was 21 +/- 5.8 (27% improvement, range 4%-74%, P < 0.01), and Global Assessment of Functioning score was 55 +/- 6.5 (12% improvement, range 4%-29%, P < 0.05). Of the 11 participants, 6 were considered responders (decrease in YBOCS & Dagger;35%) and 4 partial responders (decrease in YBOCS 25%-34%). Surgical adverse events included 1 case of skin infection leading to reimplantation. The most common transient stimulation-related side effects were anxiety and insomnia. CONCLUSIONS: BNST DBS is a promising therapy in severe therapy-refractory OCD. Our results are in line with previous publications regarding effect and safety profile. Nevertheless, DBS for OCD remains an investigational therapy and should therefore be performed in multidisciplinary clinical studies.

Automated summary

DBS in the BNST shows promising clinical outcomes in severe therapy-refractory OCD, with improvements in YBOCS, MADRS, and Global Assessment of Functioning scores. However, further multidisciplinary clinical studies are needed to confirm the efficacy and safety of this treatment.